Last updated on September 2017

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer


Brief description of study

Diarrhoea is the most commonly reported adverse events (AE) associated with Lapatinib treatment, and is also commonly associated with Capecitabine treatment. Although these events are generally mild to moderate in severity, diarrhoea adversely affects the tolerability of cancer treatment, and in severe cases diarrhoea has the potential to affect the efficacy of treatment due to poor compliance, or treatment interruption or withdrawal. The efficacy of Octreotide in the management of cancer treatment-associated diarrhoea has not been extensively evaluated in large, well-controlled studies. This is a randomised, multi-centre, open-label Phase II study in subjects with Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer which has progressed following prior therapy, which must have included anthracyclines and taxanes and therapy with Trastuzumab in the metastatic setting. This study is not placebo controlled, and there is no active comparator. The study will evaluate whether the prophylactic use of Octreotide Long Acting Release (LAR) offers a clinically meaningful benefit by reducing the frequency and severity of diarrhoea associated with treatment with Lapatinib and Capecitabine. Study completion for a subject will be defined as the completion of 24 weeks of treatment with Lapatinib and Capecitabine, or progression of cancer or the death of the subject during treatment, whichever occurs first. Approximately 140 subjects will be randomized out of which 70 will receive octreotide and 70 will receive no Octreotide

Clinical Study Identifier: NCT02294786

Find a site near you

Start Over

Novartis Investigative Site

Montpellier Cedex 5, France
  Connect »

Novartis Investigative Site

Khantymansiysk, Russian Federation
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Nizhniy Novgorod, Russian Federation
  Connect »

Novartis Investigative Site

Obninsk, Russian Federation
  Connect »

Novartis Investigative Site

Ryazan, Russian Federation
  Connect »

Novartis Investigative Site

St. Petersburg, Russian Federation
  Connect »

Novartis Investigative Site

Tomsk, Russian Federation
  Connect »

Novartis Investigative Site

Yaroslavl, Russian Federation
  Connect »

Novartis Investigative Site

Nottingham, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.